Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 34Urinary Bladder Neoplasms 29Neoplasm Metastasis 20Lung Neoplasms 19Ovarian Neoplasms 18Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Neoplasms 13Nasopharyngeal Carcinoma 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Recurrence 9Fallopian Tube Neoplasms 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Hodgkin Disease 4Colonic Neoplasms 4

Interventions

Specimen Handling 4Fluorouracil 4Bevacizumab 4fludarabine 3aldesleukin 3Radiosurgery 3Gemcitabine 3Endoscopic Mucosal Resection 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3Surveys and Questionnaires 2Sunitinib 2Pemetrexed 2Oxaliplatin 2Leucovorin 2IDRX-42 2Folfox protocol 2trastuzumab deruxtecan 1tislelizumab 1sodium thiosulfate 1sodium propionate 1semaglutide 1repotrectinib 1plecanatide 1pembrolizumab 1patritumab deruxtecan 1palbociclib 1linaclotide 1isosorbide-5-mononitrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Gemcitabine × 90 days × Clear all
NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Verastem, Inc.

Phase 1/2 Recruiting
295 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
1,130 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡